Gout

The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!

Febuxostat, a nonpurine xanthine oxidase inhibitor used in the treatment of chronic gout to lower serum urate levels, received bad press in 2019 after the US Food and Drug Administration (FDA) placed…

Pegloticase, a mammalian PEGylated recombinant uricase is approved for chronic refractory gout treatment. It decreases the serum uric acid and the signs and symptoms of gout. High titer anti-drug…

ACR20 convergence highlights a shift in gout management and uric acid lowering therapy (ULT). The new biologics pegdriticase and pegloticase are associated with risk of immunogenicity and loss of…

The RheumNow faculty reporters have been glued to their monitors all day, viewing video, reading and listening to abstract presentations and I charged them to earmark those presentations were the “…

Each pharmaceutical company has spent months and years preparing to present and highlight their featured clinical trials and abstracts at ACR 2020.  This is our selection of their best studies…

Here is the last of our QD Clinics in Podcast form, just before we start ACR2020 coverage. In this compilation from the past week we talk about - HIV and arthritis - Hyperuricemia in PsA - An odd…